Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | GBA1 | P04062 | 12/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26517333 | 0.91 | EPHX2 (0.53) | EPHX2GBA1GGPS1HRH4HRH3 | |
| SCHEMBL12640254 | 0.90 | HDAC1 (0.46) | EPHX2GBA1CSNK2A1HDAC1GGPS1 | |
| SCHEMBL13209312 | 0.87 | FFAR1 (0.46) | EPHX2GBA1CYP19A1 | |
| SCHEMBL17776274 | 0.87 | EPHX2 (0.46) | EPHX2GBA1CSNK2A1HDAC1HRH4 | |
| SCHEMBL18289680 | 0.87 | CYP19A1 (0.41) | EPHX2CYP19A1CSNK2A1HDAC1GGPS1 | |
| SCHEMBL13437065 | 0.86 | FOLH1 (0.46) | EPHX2CSNK2A1HDAC1 | |
| SCHEMBL18768813 | 0.86 | EPHX2 (0.51) | EPHX2GBA1HDAC1 | |
| SCHEMBL23221642 | 0.84 | EPHX2 (0.50) | EPHX2GBA1CYP19A1HRH4HRH3 | |
| SCHEMBL19704881 | 0.84 | EPHX2 (0.45) | EPHX2GBA1CSNK2A1HDAC1HRH4 | |
| SCHEMBL21309983 | 0.83 | EPHX2 (0.44) | EPHX2GBA1CSNK2A1HDAC1GGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016019340-A1 | POLYOXAZOLINE ANTIBODY DRUG CONJUGATES | SERINA THERAPEUTICS, INC. (US) | 2016-02-04 | — | — | WO | disclosed |